Blog

July 25, 2026

Humanin: The Overlooked Mitochondrial Survival Peptide After Viral Illness

Humanin is a mitochondrial-derived peptide that governs cell survival under stress. Emerging research links its post-viral collapse to Long COVID fatigue, PEM, and bioenergetic failure — here's the evidence, the mechanism, and the intervention landscape.
July 20, 2026

HBOT for Long COVID: Mitochondrial Rescue, Neuroinflammation Reversal & the Efrati Protocol

HBOT for Long COVID targets bioenergetic failure at the mitochondrial level — not just symptoms. The 2022 Efrati RCT showed significant cognitive improvements, increased cerebral blood flow, and durable neuroplastic remodeling. Here's the full clinical breakdown.
July 10, 2026

LDN for Long COVID Brain Fog: The NIH RECOVER Trial 2026 Evidence

LDN for Long COVID brain fog is now an NIH priority. The 2026 RECOVER-TLC trial is enrolling 1,300 participants to generate FDA-grade evidence. Here's what the microglial suppression mechanism means for high-performing professionals who haven't fully recovered cognitively from COVID.
June 20, 2026

NLRP3 Inflammasome & Long COVID Neuroinflammation: The Master Switch Driving Brain Fog and Fatigue

The NLRP3 inflammasome is now confirmed as the master molecular switch behind Long COVID neuroinflammation, brain fog, chronic fatigue, and mood dysregulation. A landmark 2026 study explains why — and what you can do about it right now.
June 15, 2026

Urolithin A Mitophagy: The Post-Viral Immune Recovery Protocol Backed by 2025 RCT Data

Urolithin A activates PINK1/Parkin mitophagy to clear damaged mitochondria from exhausted immune cells — restoring naive CD8+ T cells and raising the PEM threshold. Here is the full mechanistic breakdown and protocol stack for Long COVID and ME/CFS recovery.
May 16, 2026

EBV Reactivation & Long COVID Microaggregates: The Dual-Hit Mechanism Driving Chronic Fatigue

EBV reactivation and Long COVID microaggregates create a compounding dual-hit mechanism driving post-viral fatigue in finance professionals. Discover the 4-layer evidence-backed clinical protocol, including the 2026 Wick et al. data showing 78% improvement with combined antiviral and anti-thrombotic therapy.
April 17, 2026

Stellate Ganglion Block Long COVID POTS: 2026 STAR-CO Trial & Autonomic Reset Protocol (Part 2)

The first dedicated RCT of stellate ganglion block for Long COVID POTS launched in 2026. Here's everything that's changed: the STAR-CO trial protocol, the Frontiers in Neuroscience editorial endorsement, new mechanistic data on catecholamine-driven mitochondrial uncoupling, and the updated clinical protocol for autonomic reset.
April 7, 2026

Stellate Ganglion Block for Long COVID Dysautonomia: The 2026 STAR-CO Trial Evidence

Stellate ganglion block for Long COVID dysautonomia has entered formal NIH clinical validation in 2026. We break down the STAR-CO trial, the cervical sympathetic mechanism, catecholamine-driven mitochondrial uncoupling, and the full SGB stacking protocol for finance professionals.
April 1, 2026

Photobiomodulation Long COVID Brain Fog: The 2026 Lancet RCT Breakdown

The January 2026 Lancet eClinicalMedicine RCT tested home-based intranasal and transcranial photobiomodulation in Long COVID patients with brain fog. Near-infrared light targets cytochrome c oxidase — the suppressed rate-limiting enzyme of neuronal ATP production — restoring bioenergetic function while dampening microglial neuroinflammation.